Skip to main content
Erschienen in: Journal of Bone and Mineral Metabolism 6/2018

09.11.2017 | Original Article

Effect of prednisone treatment for 30 and 90 days on bone metabolism in collagen-induced arthritis (CIA) rats

verfasst von: Xinle Zhang, Xuna Wu, Yalin Min, Jiaqi Lu, Xuemei Zhang, Wenshuang Chen, Liyi Zou, Xiaohua Lv, Liao Cui, Bilian Xu

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Glucocorticoids (GCs) are often prescribed to treat rheumatoid arthritis (RA) in the long term, but there is still controversy in the administration of GCs, mainly because of the adverse reactions such as osteoporosis. Numerous studies have demonstrated that osteoporosis could be induced by GCs in normal rats. However, few experiments have focused on whether osteoporosis could be induced or aggravated by GCs in collagen induced arthritis (CIA) rats. We have investigated bone changes in CIA rats treated with prednisone at 4.5 mg/kg/day for 30 and 90 days by bone histomorphometry, bone mineral density (BMD), micro-CT, biomechanical test, and enzyme-linked immunosorbant assay. We found that high bone turnover osteoporosis was shown in CIA rats. Prednisone treatment for 30 and 90 days improved articular structure and decelerated the degeneration of the femur in CIA rats, but did not improve BMD and bone biomechanics. We conclude that osteoporosis was not aggravated in CIA rats treated with prednisone for 30 and 90 days. On the contrary, prednisone treatment for 30 and 90 days could prevent bone loss of the femur in CIA rats. There was a negative effect on bone metabolism in CIA rats treated with prednisone for 90 days.
Literatur
1.
Zurück zum Zitat van Everdingen AA, Siewertsz VRD, Jacobs JW, Bijlsma JW (2003) Low-dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures? Clin Exp Rheumatol 21:155–160PubMed van Everdingen AA, Siewertsz VRD, Jacobs JW, Bijlsma JW (2003) Low-dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures? Clin Exp Rheumatol 21:155–160PubMed
2.
Zurück zum Zitat den Uyl D, van Raalte DH, Nurmohamed MT, Lems WF, Bijlsma JW, Hoes JN, Dijkmans BA, Diamant M (2012) Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum 64:639–646CrossRef den Uyl D, van Raalte DH, Nurmohamed MT, Lems WF, Bijlsma JW, Hoes JN, Dijkmans BA, Diamant M (2012) Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum 64:639–646CrossRef
3.
Zurück zum Zitat Bae SC, Corzillius M, Kuntz KM, Liang MH (2003) Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. Rheumatology (Oxford) 42:46–53CrossRef Bae SC, Corzillius M, Kuntz KM, Liang MH (2003) Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. Rheumatology (Oxford) 42:46–53CrossRef
4.
Zurück zum Zitat van Everdingen AA, Jacobs JW, Siewertsz VRD, Bijlsma JW (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136:1–12CrossRef van Everdingen AA, Jacobs JW, Siewertsz VRD, Bijlsma JW (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136:1–12CrossRef
5.
Zurück zum Zitat Wu Q, Xiong X, Zhang X, Lu J, Zhang X, Chen W, Wu T, Cui L, Liu Y, Xu B (2016) Secondary osteoporosis in collagen-induced arthritis rats. J Bone Miner Metab 34:500–516CrossRef Wu Q, Xiong X, Zhang X, Lu J, Zhang X, Chen W, Wu T, Cui L, Liu Y, Xu B (2016) Secondary osteoporosis in collagen-induced arthritis rats. J Bone Miner Metab 34:500–516CrossRef
6.
Zurück zum Zitat Brand DD, Latham KA, Rosloniec EF (2007) Collagen-induced arthritis. Nat Protoc 2:1269–1275CrossRef Brand DD, Latham KA, Rosloniec EF (2007) Collagen-induced arthritis. Nat Protoc 2:1269–1275CrossRef
7.
Zurück zum Zitat Sajti E, van Meeteren N, Kavelaars A, van der Net J, Gispen WH, Heijnen C (2004) Individual differences in behavior of inbred Lewis rats are associated with severity of joint destruction in adjuvant-induced arthritis. Brain Behav Immun 18:505–514CrossRef Sajti E, van Meeteren N, Kavelaars A, van der Net J, Gispen WH, Heijnen C (2004) Individual differences in behavior of inbred Lewis rats are associated with severity of joint destruction in adjuvant-induced arthritis. Brain Behav Immun 18:505–514CrossRef
8.
Zurück zum Zitat Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de RC, Joosten LA, van den Berg WB (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50:650–659CrossRef Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de RC, Joosten LA, van den Berg WB (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50:650–659CrossRef
9.
Zurück zum Zitat Douni E, Sfikakis PP, Haralambous S, Fernandes P, Kollias G (2004) Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols. Arthritis Res Ther 6:R65–R72CrossRef Douni E, Sfikakis PP, Haralambous S, Fernandes P, Kollias G (2004) Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols. Arthritis Res Ther 6:R65–R72CrossRef
10.
Zurück zum Zitat Vidal B, Cascao R, Vale AC, Cavaleiro I, Vaz MF, Brito JA, Canhao H, Fonseca JE (2015) Arthritis induces early bone high turnover, structural degradation and mechanical weakness. PLoS ONE 10:e117100 Vidal B, Cascao R, Vale AC, Cavaleiro I, Vaz MF, Brito JA, Canhao H, Fonseca JE (2015) Arthritis induces early bone high turnover, structural degradation and mechanical weakness. PLoS ONE 10:e117100
11.
Zurück zum Zitat Takagi T, Tsao PW, Totsuka R, Suzuki T, Murata T, Takata I (1998) Dexamethasone prevents the decrease of bone mineral density in type II collagen-induced rat arthritis model. Jpn J Pharmacol 78:225–228CrossRef Takagi T, Tsao PW, Totsuka R, Suzuki T, Murata T, Takata I (1998) Dexamethasone prevents the decrease of bone mineral density in type II collagen-induced rat arthritis model. Jpn J Pharmacol 78:225–228CrossRef
12.
Zurück zum Zitat Hickling P, Jacoby RK, Kirwan JR (1998) Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol 37:930–936CrossRef Hickling P, Jacoby RK, Kirwan JR (1998) Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol 37:930–936CrossRef
13.
Zurück zum Zitat Kroot EJ, Huisman AM, Van Zeben J, Wouters JM, Van Paassen HC (2006) Oral pulsed dexamethasone therapy in early rheumatoid arthritis: a pilot study. Ann N Y Acad Sci 1069:300–306CrossRef Kroot EJ, Huisman AM, Van Zeben J, Wouters JM, Van Paassen HC (2006) Oral pulsed dexamethasone therapy in early rheumatoid arthritis: a pilot study. Ann N Y Acad Sci 1069:300–306CrossRef
14.
Zurück zum Zitat Buttgereit F, Mehta D, Kirwan J, Szechinski J, Boers M, Alten RE, Supronik J, Szombati I, Romer U, Witte S, Saag KG (2013) Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 72:204–210CrossRef Buttgereit F, Mehta D, Kirwan J, Szechinski J, Boers M, Alten RE, Supronik J, Szombati I, Romer U, Witte S, Saag KG (2013) Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 72:204–210CrossRef
15.
Zurück zum Zitat Engvall IL, Svensson B, Boonen A, van der Heijde D, Lerner UH, Hafstrom I (2013) Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP—a possible mechanism for specific inhibition of radiological destruction. Rheumatology (Oxford) 52:733–742CrossRef Engvall IL, Svensson B, Boonen A, van der Heijde D, Lerner UH, Hafstrom I (2013) Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP—a possible mechanism for specific inhibition of radiological destruction. Rheumatology (Oxford) 52:733–742CrossRef
16.
Zurück zum Zitat Kirwan JR (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 333:142–146CrossRef Kirwan JR (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 333:142–146CrossRef
17.
Zurück zum Zitat Gotzsche PC, Johansen HK (1998) Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 316:811–818CrossRef Gotzsche PC, Johansen HK (1998) Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 316:811–818CrossRef
18.
Zurück zum Zitat Lems WF, Gerrits MI, Jacobs JW, van Vugt RM, van Rijn HJ, Bijlsma JW (1996) Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis 55:288–293CrossRef Lems WF, Gerrits MI, Jacobs JW, van Vugt RM, van Rijn HJ, Bijlsma JW (1996) Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis 55:288–293CrossRef
19.
Zurück zum Zitat Neeck G, Kluter A, Dotzlaw H, Eggert M (2002) Involvement of the glucocorticoid receptor in the pathogenesis of rheumatoid arthritis. Ann N Y Acad Sci 966:491–495CrossRef Neeck G, Kluter A, Dotzlaw H, Eggert M (2002) Involvement of the glucocorticoid receptor in the pathogenesis of rheumatoid arthritis. Ann N Y Acad Sci 966:491–495CrossRef
20.
Zurück zum Zitat Goecke A, Guerrero J (2006) Glucocorticoid receptor beta in acute and chronic inflammatory conditions: clinical implications. Immunobiology 211:85–96CrossRef Goecke A, Guerrero J (2006) Glucocorticoid receptor beta in acute and chronic inflammatory conditions: clinical implications. Immunobiology 211:85–96CrossRef
21.
Zurück zum Zitat Manenschijn L, van den Akker EL, Lamberts SW, van Rossum EF (2009) Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann N Y Acad Sci 1179:179–198CrossRef Manenschijn L, van den Akker EL, Lamberts SW, van Rossum EF (2009) Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann N Y Acad Sci 1179:179–198CrossRef
22.
Zurück zum Zitat Cavalcante LO, Melo MR, Dinis VG, Castro RB, Souza BD, Longui CA (2010) Quantitation of glucocorticoid receptor alpha and NF-kappaB pathway mRNA and its correlation with disease activity in rheumatoid arthritis patients. Genet Mol Res 9:2300–2310CrossRef Cavalcante LO, Melo MR, Dinis VG, Castro RB, Souza BD, Longui CA (2010) Quantitation of glucocorticoid receptor alpha and NF-kappaB pathway mRNA and its correlation with disease activity in rheumatoid arthritis patients. Genet Mol Res 9:2300–2310CrossRef
23.
Zurück zum Zitat Earp JC, Dubois DC, Molano DS, Pyszczynski NA, Keller CE, Almon RR, Jusko WJ (2008) Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats. J Pharmacol Exp Ther 326:532–545CrossRef Earp JC, Dubois DC, Molano DS, Pyszczynski NA, Keller CE, Almon RR, Jusko WJ (2008) Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats. J Pharmacol Exp Ther 326:532–545CrossRef
24.
Zurück zum Zitat Earp JC, Dubois DC, Molano DS, Pyszczynski NA, Almon RR, Jusko WJ (2008) Modeling corticosteroid effects in a rat model of rheumatoid arthritis II: mechanistic pharmacodynamic model for dexamethasone effects in Lewis rats with collagen-induced arthritis. J Pharmacol Exp Ther 326:546–554CrossRef Earp JC, Dubois DC, Molano DS, Pyszczynski NA, Almon RR, Jusko WJ (2008) Modeling corticosteroid effects in a rat model of rheumatoid arthritis II: mechanistic pharmacodynamic model for dexamethasone effects in Lewis rats with collagen-induced arthritis. J Pharmacol Exp Ther 326:546–554CrossRef
25.
Zurück zum Zitat Ishida O, Furuya T, Inoue E, Ochi K, Ikari K, Taniguchi A, Yamanaka H, Momohara S (2015) Risk factors for established vertebral fractures in Japanese patients with rheumatoid arthritis: results from a large prospective observational cohort study. Mod Rheumatol 25:373–378CrossRef Ishida O, Furuya T, Inoue E, Ochi K, Ikari K, Taniguchi A, Yamanaka H, Momohara S (2015) Risk factors for established vertebral fractures in Japanese patients with rheumatoid arthritis: results from a large prospective observational cohort study. Mod Rheumatol 25:373–378CrossRef
26.
Zurück zum Zitat Pereira RM, Delany AM, Canalis E (2001) Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 28:484–490CrossRef Pereira RM, Delany AM, Canalis E (2001) Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 28:484–490CrossRef
27.
Zurück zum Zitat Smith E, Coetzee GA, Frenkel B (2002) Glucocorticoids inhibit cell cycle progression in differentiating osteoblasts via glycogen synthase kinase-3beta. J Biol Chem 277:18191–18197CrossRef Smith E, Coetzee GA, Frenkel B (2002) Glucocorticoids inhibit cell cycle progression in differentiating osteoblasts via glycogen synthase kinase-3beta. J Biol Chem 277:18191–18197CrossRef
28.
Zurück zum Zitat Warriner AH, Saag KG (2013) Prevention and treatment of bone changes associated with exposure to glucocorticoids. Curr Osteoporos Rep 11:341–347CrossRef Warriner AH, Saag KG (2013) Prevention and treatment of bone changes associated with exposure to glucocorticoids. Curr Osteoporos Rep 11:341–347CrossRef
29.
Zurück zum Zitat Hofbauer LC, Kuhne CA, Viereck V (2004) The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 4:268–275PubMed Hofbauer LC, Kuhne CA, Viereck V (2004) The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 4:268–275PubMed
30.
Zurück zum Zitat Giner M, Rios MA, Montoya MA, Vazquez MA, Naji L, Perez-Cano R (2009) RANKL/OPG in primary cultures of osteoblasts from post-menopausal women. Differences between osteoporotic hip fractures and osteoarthritis. J Steroid Biochem Mol Biol 113:46–51CrossRef Giner M, Rios MA, Montoya MA, Vazquez MA, Naji L, Perez-Cano R (2009) RANKL/OPG in primary cultures of osteoblasts from post-menopausal women. Differences between osteoporotic hip fractures and osteoarthritis. J Steroid Biochem Mol Biol 113:46–51CrossRef
31.
Zurück zum Zitat Yasuda H (2013) RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases. World J Orthop 4:207–217CrossRef Yasuda H (2013) RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases. World J Orthop 4:207–217CrossRef
Metadaten
Titel
Effect of prednisone treatment for 30 and 90 days on bone metabolism in collagen-induced arthritis (CIA) rats
verfasst von
Xinle Zhang
Xuna Wu
Yalin Min
Jiaqi Lu
Xuemei Zhang
Wenshuang Chen
Liyi Zou
Xiaohua Lv
Liao Cui
Bilian Xu
Publikationsdatum
09.11.2017
Verlag
Springer Japan
Erschienen in
Journal of Bone and Mineral Metabolism / Ausgabe 6/2018
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-017-0880-1

Weitere Artikel der Ausgabe 6/2018

Journal of Bone and Mineral Metabolism 6/2018 Zur Ausgabe

Letter to the Editor

PCOS and risk of fractures

List of Reviewers 2017-2018

LIST OF REVIEWERS 2017–2018

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.